|

Talazoparib Clinical Trials

19 actively recruiting trials across 11 locations

Also known as: BMN 673, BMN-673, BMN673, Combination product: 177Lu-DOTA-Octreotate, L01XX60 +4 more

Pipeline

Phase 1: 4Phase 2: 11Phase 1/2: 4

Top Sponsors

  • National Cancer Institute (NCI)2
  • Massachusetts General Hospital2
  • M.D. Anderson Cancer Center2
  • The Netherlands Cancer Institute1
  • St. Jude Children's Research Hospital1

Indications

  • Cancer19
  • Breast Cancer5
  • Recurrent Ovarian Carcinoma2
  • Stage IV Ovarian Cancer AJCC v82
  • Stage IV Prostate Cancer AJCC v82

Other5 trials

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
Phase 2
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Phase 1
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Phase 1/2
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Duarte, California3 trials

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

Phase 2
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

City of Hope Comprehensive Cancer Center

Phase 2

Boston, Massachusetts2 trials

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Dana Farber Cancer Institute

Phase 2
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Massachusetts General Hospital Cancer Center

Phase 1/2

Birmingham, Alabama1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Phoenix, Arizona1 trial

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Phoenix Children's Hospital

Phase 1

Palo Alto, California1 trial

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Lucille Packard Children's Hospital Stanford

Phase 1/2

San Francisco, California1 trial

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

UCSF Medical Center-Mission Bay/Benioff Children's Hospital

Phase 2

Gainesville, Florida1 trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

UF Health Cancer Institute - Gainesville

Phase 2

Baltimore, Maryland1 trial

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Johns Hopkins University/Sidney Kimmel Cancer Center

Phase 1

Philadelphia, Pennsylvania1 trial

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Fox Chase Cancer Center - Philadelphia

Phase 1

Pittsburgh, Pennsylvania1 trial

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

University of Pittsburgh Medical Center

Phase 2

Houston, Texas1 trial

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.